Literature DB >> 1833819

A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.

A Bellacosa1, J R Testa, S P Staal, P N Tsichlis.   

Abstract

The v-akt oncogene codes for a 105-kilodalton fusion phosphoprotein containing Gag sequences at its amino terminus. Sequence analysis of v-akt and biochemical characterization of its product revealed that it codes for a protein kinase C-related serine-threonine kinase whose cellular homolog is expressed in most tissues, with the highest amount found in thymus. Although Akt is a serine-threonine kinase, part of its regulatory region is similar to the Src homology-2 domain, a structural motif characteristic of cytoplasmic tyrosine kinases that functions in protein-protein interactions. This suggests that Akt may form a functional link between tyrosine and serine-threonine phosphorylation pathways.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833819     DOI: 10.1126/science.1833819

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  246 in total

1.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

Authors:  N Nakamura; S Ramaswamy; F Vazquez; S Signoretti; M Loda; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.

Authors:  R Swart; I K Ruf; J Sample; R Longnecker
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis.

Authors:  M P Scheid; J R Woodgett
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

Review 4.  AKT plays a central role in tumorigenesis.

Authors:  J R Testa; A Bellacosa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

5.  Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents.

Authors:  Katherine J Kayser-Bricker; Matthew P Glenn; Sang Hoon Lee; Said M Sebti; Jin Q Cheng; Andrew D Hamilton
Journal:  Bioorg Med Chem       Date:  2008-09-27       Impact factor: 3.641

6.  Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B.

Authors:  Michael P Scheid; Paola A Marignani; James R Woodgett
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

7.  Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase.

Authors:  Diana W Shineman; Aleksandra S Dain; Minkyu L Kim; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-05-05       Impact factor: 3.162

8.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Authors:  Maria Letizia Motti; Daniela Califano; Giancarlo Troncone; Carmela De Marco; Ilenia Migliaccio; Emiliano Palmieri; Luciano Pezzullo; Lucio Palombini; Alfredo Fusco; Giuseppe Viglietto
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

10.  Akt/PKB interacts with the histone H3 methyltransferase SETDB1 and coordinates to silence gene expression.

Authors:  Haidong Gao; Zhigang Yu; Dongsong Bi; Liyu Jiang; Yazhou Cui; Jingzhong Sun; Rong Ma
Journal:  Mol Cell Biochem       Date:  2007-06-19       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.